News | April 08, 2026
Merck moves to seal $53-a-share takeover of Terns Pharmaceuticals
The acquisition aims to bolster Merck’s hematology portfolio with Terns’ lead oncology candidate, TERN-701
The acquisition aims to bolster Merck’s hematology portfolio with Terns’ lead oncology candidate, TERN-701
Biopharma companies face persistent hurdles in cell line development, including long timelines, low yields, and high failure rates for novel molecules
The new capital is expected to fund the company through 2029
The financing includes a four-year interest-only period, extendable to five years if a net sales milestone is achieved
EB-003 is Enveric’s lead neuroplastogen, a 5-HT2A / 5-HT1B dual-acting compound designed to promote neuroplastic changes
Low-dose radiotherapy offers immediate pain relief, quicker recovery, and better movement through a non-invasive procedure
As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million
The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions
Lonza will take on technology transfer, process optimization, and cGMP manufacturing, leveraging its global network and expertise in highly potent compounds
This makes VLCC the sole institution in the country authorised to conduct in-person NCLC exams
Subscribe To Our Newsletter & Stay Updated
